Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company (SCLX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 8-K, registration statements, proxy materials and other key documents filed with the U.S. Securities and Exchange Commission. Scilex is an emerging growth company focused on non-opioid pain management products and related pipeline candidates, and its filings give detailed insight into corporate actions, financing structures and strategic agreements.
For investors tracking Scilex’s capital structure, recent Form 8-K reports describe warrant inducement agreements, exercises of existing warrants, issuance of new unregistered warrants, and the terms of non-recourse loan and securities pledge agreements with The St. James Bank & Trust Company Ltd. These filings outline interest rates tied to the 12-month Secured Overnight Financing Rate, maturity dates, pledged collateral (including Scilex and Datavault AI shares), events of default, and lender remedies.
Filings also document Scilex’s Datavault AI transactions, including a Securities Purchase Agreement for Datavault common stock and a pre-funded warrant, and a License Agreement granting Scilex a worldwide, exclusive license to Datavault patents and know-how for biotech, biopharma, genetic, diagnostic and data-related markets. The associated 8-Ks summarize consideration, royalty structures, milestones and termination conditions.
Scilex’s registration statements, such as its S-1 filing, and proxy statements (DEF 14A) provide further detail on equity incentive plans, option repricing proposals, voting rights for common and preferred stock, and governance matters. These documents complement the company’s periodic reports by explaining how management structures compensation and seeks shareholder approvals for key actions.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting material agreements, financial obligations, equity issuances, and risk disclosures. Users can quickly locate information on warrant terms, loan covenants, Datavault-related agreements, and other items that shape Scilex’s financial profile and strategic direction, without manually parsing every page of each filing.
Scilex Holding Company notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 by the prescribed due date of March 31, 2026 because it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company. The company anticipates filing the Form 10-K on or before April 15, 2026.
Scilex Holding Company filed a prospectus supplement registering up to 6,685,714 shares of Common Stock (aggregate of multiple tranches, including warrants and shares issuable upon exercise) as an update to prospectuses dated May 13, 2025.
The supplement attaches Current Reports on Form 8-K that disclose several corporate actions: a $20.0 million convertible note to Q Scan that converted into 140,379,226 Q Scan shares and a related agreement to purchase 193,021,436 Q Scan shares for approximately $27.5 million; elimination of the previously designated 5,000,000 Series 1 Mandatory Exchangeable Preferred Stock; and a Warrant Agreement with Oramed issuing a 100,000-warrant issuance (the "February 2026 Warrant") exercisable at an initial price of $20.00, subject to adjustment, with a 4.99% beneficial ownership cap (adjustable to 9.99% with notice) and an expiration of December 13, 2029. The supplement notes a 1-for-35 reverse stock split effective April 15, 2025 and reports last reported share and warrant prices as of February 19, 2026 of $8.01 and $0.15, respectively.
Scilex Holding Company files a prospectus supplement updating prior prospectuses and registering up to 6,685,714 shares of Common Stock and related instruments.
The supplement incorporates three Current Reports on Form 8-K dated January 29, 2026, February 2, 2026 and February 19, 2026, and attaches them to the prospectus. It discloses a $20.0 million convertible loan to Q Scan that converted into 140,379,226 Q Scan shares and a related stock purchase agreement to buy 193,021,436 Q Scan shares for approximately $27.5 million. It also describes a Warrant Agreement with Oramed that issued 100,000 warrants at an initial exercise price of $20.00 per share (floor price $8.22), exercisable through December 13, 2029, with a 4.99% beneficial ownership exercise cap (adjustable up to 9.99% with notice).
Scilex Holding Company files a prospectus supplement that updates multiple registration statements to register up to 6,685,714 shares of common stock and related instruments.
The supplement incorporates three prospectuses and attaches Current Reports on Form 8-K dated February 2, 2026 and February 19, 2026. It discloses a $20.0 million convertible note to Q Scan that converted into Q Scan common stock, a pending Stock Purchase of 193,021,436 Q Scan shares for approximately $27.5 million, revocation and elimination of a previously designated 5,000,000 share Series 1 preferred designation, and a Warrant Agreement with Oramed issuing a 100,000-warrant instrument exercisable at $20.00 (floor adjustment $8.22) expiring December 13, 2029.
Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals under which Oramed deferred an amortization payment on Scilex’s Tranche B senior secured convertible note that had been scheduled for October 1, 2025. In exchange, Scilex agreed to issue Oramed a new warrant to purchase 100,000 shares of common stock at an initial exercise price of $20.00 per share, called the February 2026 Warrant. The deferred amortization payment was ultimately made in November 2025, and the warrant is immediately exercisable and expires on December 13, 2029.
Scilex committed to file a registration statement to register the resale by Oramed of the shares issuable upon exercise, or to include them in another Form S-3. The warrant includes price-adjustment mechanisms, subject to a floor of $8.22 per share, a beneficial ownership cap initially at 4.99% (optionally adjustable up to 9.99% with notice), cashless exercise if no effective registration is available, and change-of-control protections allowing Oramed to require cash repurchase based on Black Scholes value.
Scilex Holding Company’s Schedule 13G/A Amendment No. 4 reports that Oramed Pharmaceuticals Inc. beneficially owns 437,510 shares of Scilex common stock, representing 4.9% of the outstanding class. These shares are issuable upon exercise of warrants and conversion of convertible notes that are exercisable within 60 days.
The ownership percentage is calculated using 8,491,267 Scilex common shares outstanding as of December 5, 2025, plus the 437,510 shares underlying Oramed’s instruments. Oramed states the securities were not acquired and are not held for the purpose of changing or influencing control of Scilex.
Scilex Holding Company announced that its board of directors has revoked a previously declared stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock. This preferred stock had been authorized but no shares were ever issued.
In connection with the revocation, Scilex filed a Certificate of Elimination in Delaware, which became effective upon filing. This action eliminated the Series 1 designation and returned the 5,000,000 preferred shares to the company’s pool of undesignated preferred stock, effectively ending the special series that had been created for the contemplated dividend.
Scilex Holding Company entered into a financing and equity transaction with Quantum Scan Holdings, Inc. (Q Scan). Scilex loaned Q Scan $20 million under a convertible promissory note dated January 29, 2026, which fully converted that same day into 140,379,226 shares of Q Scan common stock.
Separately, Scilex agreed in a common stock purchase agreement to buy an additional 193,021,436 Q Scan shares for an aggregate price of approximately $27.5 million, with closing to occur within five business days after Q Scan delivers written notice. Scilex’s Chief Financial Officer, Stephen Ma, has served as Q Scan’s interim CFO since January 16, 2026 and, as of this report, has not received compensation from Q Scan in that role.